Fulcrum Therapeutics, Inc. (FULC) Financials
FULC Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 257.7 million | 22.5 million |
2023-09-30 | 278.9 million | 23.4 million |
2023-06-30 | 300.3 million | 24.9 million |
2023-03-31 | 321.1 million | 24.9 million |
FULC Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -23.2 million | 3.4 million |
2023-09-30 | -23.0 million | 3.7 million |
2023-06-30 | -21.0 million | 3.4 million |
2023-03-31 | -24.3 million | 4.3 million |
FULC Net Income
No data available :(
FULC Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 236.2 million | - | 10.8 million |
2023-09-30 | 257.1 million | - | 11.5 million |
2023-06-30 | 278.2 million | - | 12.2 million |
2023-03-31 | 297.8 million | - | 12.8 million |
FULC Shares Outstanding
FULC Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 77000 | 19.0 million | 9.9 million | 508000 |
2023-09-30 | 65000 | 18.2 million | 10.0 million | - |
2023-06-30 | 195000 | 17.8 million | 10.3 million | - |
2023-03-31 | 171000 | 16.7 million | 11.5 million | - |
FULC Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 871000 | 508000 |
2023-09-30 | 759000 | 500000 |
2023-06-30 | 880000 | 600000 |
2023-03-31 | 295000 | 566000 |
FULC
Price: $7.51
52 week price:
Earnings Per Share: -1.59 USD
P/E Ratio: -4.91
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 493900
Market Capitalization: 527.7 million